Search

Displaying results 5181 - 5190 of 10000 in total
  1. Drug

    Vespula maculifrons venom protein

    go.drugbank.com/drugs/DB10956
    Approved

    Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.

  2. Drug

    Polistes annularis venom protein

    go.drugbank.com/drugs/DB11027
    Approved

    Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.

  3. Drug

    Vespula germanica venom protein

    go.drugbank.com/drugs/DB11030
    Approved

    Vespula germanica venom protein is an extract of Vespula germanica venom. Vespula germanica venom protein is used in allergenic testing.

  4. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  5. Drug

    Brivudine

    go.drugbank.com/drugs/DB03312
    ApprovedInvestigational

    Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.

  6. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  7. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  8. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

  9. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

  10. Drug

    Iratumumab

    go.drugbank.com/drugs/DB05550
    Investigational

    Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.